Prospective, Double-blind, Randomized, Multicenter Phase III Study Evaluating Efficacy and Safety of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy

Trial Profile

Prospective, Double-blind, Randomized, Multicenter Phase III Study Evaluating Efficacy and Safety of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2018

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Chronic inflammatory demyelinating polyradiculoneuropathy
  • Focus Registrational; Therapeutic Use
  • Sponsors Octapharma
  • Most Recent Events

    • 22 Feb 2018 This trial has been suspended in Denmark as per European Clinical Trials Database record..
    • 18 Sep 2017 Planned initiation date changed from 1 Aug 2017 to 1 Nov 2017.
    • 03 Aug 2017 Planned initiation date changed from 1 May 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top